Lucid Diagnostics (NASDAQ:LUCD) Given New $2.00 Price Target at Cantor Fitzgerald

Lucid Diagnostics (NASDAQ:LUCD) had its price objective cut by Cantor Fitzgerald from $3.00 to $2.00 in a report issued on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other equities research analysts have also issued reports about the stock. Ascendiant Capital Markets dropped their price objective on shares of Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating on the stock in a report on Tuesday, September 10th. Canaccord Genuity Group reissued a “buy” rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a report on Thursday. Canaccord Genuity Group raised Lucid Diagnostics to a “strong-buy” rating in a report on Tuesday, August 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $2.50 target price on shares of Lucid Diagnostics in a research report on Thursday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $3.69.

Lucid Diagnostics Stock Performance

LUCD stock traded down $0.02 during trading on Friday, reaching $0.99. The company had a trading volume of 428,162 shares, compared to its average volume of 195,200. Lucid Diagnostics has a twelve month low of $0.63 and a twelve month high of $1.58. The company has a market cap of $53.28 million, a price-to-earnings ratio of -0.87 and a beta of 1.41. The firm has a 50-day simple moving average of $0.87 and a 200-day simple moving average of $0.85.

Hedge Funds Weigh In On Lucid Diagnostics

An institutional investor recently raised its position in Lucid Diagnostics stock. Virtu Financial LLC boosted its stake in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,671 shares of the company’s stock after acquiring an additional 13,835 shares during the quarter. Virtu Financial LLC owned 0.07% of Lucid Diagnostics worth $28,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.